Navigation Links
CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
Date:6/16/2009

euronal damage is also implicated in the peripheral neuropathies associated with diabetes, kidney disease, cancer chemotherapy and other conditions. In preclinical studies, CXB909 enhanced the action of NGF in vitro, amplifying its activity almost seven-fold. CXB909 was neuroprotective in a variety of cellular assays and in animal models of neuropathies and neurodegenerative diseases, including chemotherapy-induced neuropathy, for which there is currently no approved treatment.

"The addition of CXB909 to our development pipeline is another example of the growing success of our strategy to in-license novel CNS agents with validated mechanisms for the treatment of underserved CNS disorders," said Barry Brand, Chief Executive Officer of CeNeRx. "Our rapidly aging population is at risk for devastating neuropathic and neurodegenerative diseases that lack effective therapies. We intend to move quickly to test CXB909 in relevant conditions, beginning with chemotherapy-induced peripheral neuropathy, a disabling and dose-limiting side effect of cancer treatment with a relatively straightforward pathway to clinical development and regulatory review."

CXB909 was licensed from Krenitsky Pharmaceuticals Inc., which also licensed the RIMA series of selective and reversible monoamine oxidase inhibitor (MAOI) compounds to CeNeRx. The lead compound in that program, TriRima(TM), is currently in a Phase II trial for the treatment of major depressive disorder. Further details of the new licensing agreement were not disclosed.

About CeNeRx BioPharma

CeNeRx is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx's most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advant
'/>"/>

SOURCE CeNeRx BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)
2. CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
5. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
7. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
8. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
9. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
10. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
11. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  CAS Medical Systems, Inc. (NASDAQ: CASM ... monitoring, today announced that Thomas M. Patton ... 2 nd Annual Marcum MicroCap Conference on Thursday, May ... New York City . The presentation is ... 10 room and will be available via a live webcast ...
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)...  Echo Pharma Acquisition Limited ("Royalty Pharma") announced today ... Threshold from 90 percent to 50 percent of Maximum ... with the terms of the Revised Offer Document issued ... Under the terms of the Increased Offer, Royalty Pharma ... ) for $12.50 per share in cash. The Increased ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
... Shands Jacksonville Medical Center ... (NASDAQ: MASI ) today jointly announce the ... SET Pulse CO-Oximetry™ technology for advanced noninvasive patient monitoring ... also operates one of the biggest and busiest trauma ...
... 2011 The Medical Oncology Association of Southern ... signed an agreement to work together to expand ... and costs of cancer care in Southern California. ... reimbursement and distribution services to help health care ...
Cached Medicine Technology:Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 2Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 3Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 4Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 5Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities 6Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 2Medical Oncology Association of Southern California, Cardinal Health Specialty Solutions Collaborate With Payors to Improve Quality, Costs, Accessibility of Cancer Care 3
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 ... outreach program being tackled by the Safe Passage Committee ... Fullpower personal safety workshop for women on ... teaches personal safety skills programs for people of all ... us their experiences with street harassment for years,” said ...
(Date:5/23/2013)... May 23, 2013 Dimensional Insight, ... solutions, announced today that Paul Comras, director ... speak at the 2013 International Medical Users Software ... Expense & Revenue Visibility from Your General Ledger.” ... 29 from 2:30-3:25 p.m. in Azalea 1 at ...
(Date:5/23/2013)... IN (PRWEB) May 23, 2013 ... Modernfold, a DORMA company, is pleased to announce ... vinyl coverings for its pacesetting space division products. ... products and wallcoverings, the new patterns and colors ... , Through meetings with a team of ...
(Date:5/23/2013)... members of the PETA International Science Consortium, Ltd., ... Safety Improvement Act of 2013: , Reform of ... also modernizes toxicity testing. , Ensuring the ... important goal. Reforming the EPA,s Toxic Substances ... the National Research Council,s vision for transforming toxicity ...
(Date:5/23/2013)... Bronson Gray HealthDay Reporter , , WEDNESDAY, May 22 ... device used to save an infant born with a serious ... marriage of bioengineering and surgery. A report in the ... the situation that sparked the innovation. At first, the ... began to have difficulty breathing and eating when he was ...
Breaking Medicine News(10 mins):Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 2Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 3Health News:San Francisco Tenderloin Women Say “No!” to Street Harassment: Safe Passage Sponsors Kidpower Adult Safety Skills Workshops and Resources 4Health News:Dimensional Insight to Demonstrate How Hospitals Can Use Business Intelligence within MEDITECH Environments at 2013 International MUSE Conference 2Health News:Modernfold Debuts New Colors and Patterns for Space Division Products 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 2Health News:Docs Use 3-D Printer to Create Lifesaving Airway Device for Infant 3
... User,s ... HealthVault Profile, ANN ... delivers a variety of integrated healthcare services,announced that it has ... consumers collect, store, and share,health information online. The UNIVAL application, ...
... clinical nutritionist and women,s health practitioner, has formulated ... protection for beautiful skin, a strong immune system, ... vision. Dr. Lark,s Thrive! is available exclusively ... Healthy Directions, LLC, one of the largest North ...
... Every year in Jacksonville,nearly 600 adults experience ... long road to recovery lacked long-term support. Today, ... only program,in Florida created to help people with ... reintegration., The Brain Injury Association of America ...
... MADISON, N.J., Oct. 22 Wyeth (NYSE: WYE ),announced ... Ann Stribling v. Wyeth,in New Jersey State Court in ... assessed total damages of $3 million. Wyeth is reviewing,its ... finding and believe it is,unsupported by the evidence, which ...
... Utilizing a new, innovative,twist on the popular Christmas toy ... Points by Sheraton Denver Southeast and give,back to the ... and the community may donate new costumes for the,Kunsberg ... Jewish,Medical and Research Center., "The Glendale Raptors are ...
... how cancer develops , , WEDNESDAY, Oct. 22 (HealthDay News) -- ... have grown entire prostates in mice. , This feat was ... stem cells from other types of cells, according to a ... , This information still has to be confirmed in humans, ...
Cached Medicine News:Health News:UNIVAL(R), Inc. Becomes a Microsoft(R) HealthVault(TM) Application Provider 2Health News:Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits 2Health News:Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits 3Health News:Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits 4Health News:Brooks Rehabilitation Opens First Work-Based Brain Injury Rehab Program in Florida 2Health News:Glendale Raptors Join Four Points by Sheraton Denver Southeast and Animal Planet's Dr. Kevin Fitzgerald for Second Annual Halloween Costume Drive & Halloween Party for Kunsberg School at National Jewish Medical and Research Center 2Health News:New Prostrates Grown From Single Stem Cell 2
Straight 8 mm downcutting Royce blade. Can be placed in closed handle for protection. Rigid handle when folded and locked. Straight 8 mm downcutting blades. Handle length folded 109 mm, 4.3 inches....
Duckbill. 3.5 mm tip. Light curve....
2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
2 mm curved tip. Round handle. Designated most popular model or size....
Medicine Products: